SpineJournal.gr

Press Release Source: NuVasive, Inc. On Friday February 26, 2010, 4:00 pm EST
SAN DIEGO, Feb. 26 /PRNewswire-FirstCall/ — NuVasive, Inc. (Nasdaq:NUVA – News), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today that United Healthcare changed its lumbar spinal fusion policy to include coverage for the eXtreme Lateral Interbody Fusion, or XLIF procedure, published on February 26, 2010, a reversal from its previous policy that labeled XLIF as unproven. Â (more…)

–Anticipates Full Year 2009 Revenue of Approximately $370 Million
–Announces Full Year 2010 Revenue Guidance of $480 Million to $500 Million
SAN DIEGO, Jan 29, 2010 /PRNewswire via COMTEX/ — NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, today announced preliminary unaudited financial results for the full year ended December 31, 2009. (more…)

SAN DIEGO, Oct. 20 /PRNewswire-FirstCall/ – NuVasive, Inc. (Nasdaq: NUVA – News), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today financial results for the quarter ended September 30, 2009. (more…)

SAN DIEGO, April 22 /PRNewswire-FirstCall/ — NuVasive, Inc., a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today that it has agreed to purchase Cervitech® Inc., a New Jersey based company focused on clinical approval of the PCM® cervical disc system, a motion preserving total disc replacement device. This strategic acquisition allows NuVasive the potential to accelerate its entry into the growing mechanical cervical disc replacement market.

Currently, the PCM investigational device is in an FDA-approved clinical trial in the United States and two year follow up is scheduled to be completed in the fourth quarter of 2009. NuVasive anticipates submitting for FDA approval in the first quarter of 2010. The Company expects modest sales outside the U.S. in the near term, with product revenue of $100 million annually within three years of U.S. commercialization.